Optimal cut-off of homeostasis model assessment of insulin resistance (HOMA-IR) for the diagnosis of metabolic syndrome: third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007)

被引:153
作者
Esteghamati, Alireza [1 ]
Ashraf, Haleh [2 ]
Khalilzadeh, Omid [1 ]
Zandieh, Ali [1 ]
Nakhjavani, Manouchehr [1 ]
Rashidi, Armin [1 ]
Haghazali, Mehrdad [3 ]
Asgari, Fereshteh [3 ]
机构
[1] Univ Tehran Med Sci, EMRC, Vali Asr Hosp, Sch Med, Tehran, Iran
[2] Univ Tehran Med Sci, Dept Cardiol, Tehran Heart Ctr, Tehran, Iran
[3] Minist Hlth & Med Educ, Ctr Dis Control, Tehran, Iran
关键词
GLUCOSE-TOLERANCE; PREVALENCE; IDENTIFY; CRITERIA; PLASMA; INDEX; QUANTIFICATION; IDENTIFICATION; EPIDEMIOLOGY; SENSITIVITY;
D O I
10.1186/1743-7075-7-26
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 [营养与食品卫生学];
摘要
Aim: We have recently determined the optimal cut-off of the homeostatic model assessment of insulin resistance for the diagnosis of insulin resistance (IR) and metabolic syndrome (MetS) in non-diabetic residents of Tehran, the capital of Iran. The aim of the present study is to establish the optimal cut-off at the national level in the Iranian population with and without diabetes. Methods: Data of the third National Surveillance of Risk Factors of Non-Communicable Diseases, available for 3,071 adult Iranian individuals aging 25-64 years were analyzed. MetS was defined according to the Adult Treatment Panel III (ATPIII) and International Diabetes Federation (IDF) criteria. HOMA-IR cut-offs from the 50th to the 95th percentile were calculated and sensitivity, specificity, and positive likelihood ratio for MetS diagnosis were determined. The receiver operating characteristic (ROC) curves of HOMA-IR for MetS diagnosis were depicted, and the optimal cut-offs were determined by two different methods: Youden index, and the shortest distance from the top left corner of the curve. Results: The area under the curve (AUC) (95%CI) was 0.650 (0.631-0.670) for IDF-defined MetS and 0.683 (0.664-0.703) with the ATPIII definition. The optimal HOMA-IR cut-off for the diagnosis of IDF- and ATPIII-defined MetS in non-diabetic individuals was 1.775 (sensitivity: 57.3%, specificity: 65.3%, with ATPIII; sensitivity: 55.9%, specificity: 64.7%, with IDF). The optimal cut-offs in diabetic individuals were 3.875 (sensitivity: 49.7%, specificity: 69.6%) and 4.325 (sensitivity: 45.4%, specificity: 69.0%) for ATPIII- and IDF-defined MetS, respectively. Conclusion: We determined the optimal HOMA-IR cut-off points for the diagnosis of MetS in the Iranian population with and without diabetes.
引用
收藏
页数:8
相关论文
共 41 条
[1]
Acosta AM, 2002, REV MED CHILE, V130, P1227
[2]
[Anonymous], 2003, The Statistical Evaluation of Medical Tests for Classification and Prediction
[3]
[Anonymous], STEPwise approach to surveillance (STEPS)
[4]
[Anonymous], 2006, The IDF Consensus Worldwide Definition of the Metabolic Syndrome
[5]
Insulin resistance quantification by fasting insulin plasma values and HOMA index in a non-diabetic population [J].
Ascaso, JF ;
Romero, P ;
Real, JT ;
Priego, A ;
Valdecabres, C ;
Carmena, R .
MEDICINA CLINICA, 2001, 117 (14) :530-533
[6]
Balkau B, 1999, DIABETIC MED, V16, P442
[7]
Metabolic Syndrome: epidemiology and more extensive phenotypic description. Cross-sectional data from the Bruneck Study [J].
Bonora, E ;
Kiechl, S ;
Willeit, J ;
Oberhollenzer, F ;
Egger, G ;
Bonadonna, RC ;
Muggeo, M .
INTERNATIONAL JOURNAL OF OBESITY, 2003, 27 (10) :1283-1289
[8]
Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity - Studies in subjects with various degrees of glucose tolerance and insulin sensitivity [J].
Bonora, E ;
Saggiani, F ;
Targher, G ;
Zenere, MB ;
Alberiche, M ;
Monauni, T ;
Bonadonna, RC ;
Muggeo, M .
DIABETES CARE, 2000, 23 (01) :57-63
[9]
Prevalence of insulin resistance in metabolic disorders - The Bruneck Study [J].
Bonora, E ;
Kiechl, S ;
Willeit, J ;
Oberhollenzer, F ;
Egger, G ;
Targher, G ;
Alberiche, M ;
Bonadonna, RC ;
Muggeo, M .
DIABETES, 1998, 47 (10) :1643-1649
[10]
Epidemiology, trends, and morbidities of obesity and the metabolic syndrome [J].
Bray, GA ;
Bellanger, T .
ENDOCRINE, 2006, 29 (01) :109-117